Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Leases: 2020-2024

Historic Capital Leases for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $3.3 million.

  • SAB Biotherapeutics' Capital Leases fell 4.56% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 4.56%. This contributed to the annual value of $3.3 million for FY2024, which is 4.17% down from last year.
  • SAB Biotherapeutics' Capital Leases amounted to $3.3 million in FY2024, which was down 4.17% from $3.4 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Capital Leases registered a high of $3.9 million during FY2020, and its lowest value of $3.3 million during FY2024.
  • For the 3-year period, SAB Biotherapeutics' Capital Leases averaged around $3.4 million, with its median value being $3.4 million (2023).
  • Data for SAB Biotherapeutics' Capital Leases shows a maximum YoY dropped of 5.82% (in 2023) over the last 5 years.
  • Over the past 5 years, SAB Biotherapeutics' Capital Leases (Yearly) stood at $3.9 million in 2020, then decreased by 4.11% to $3.8 million in 2021, then declined by 3.53% to $3.6 million in 2022, then declined by 5.82% to $3.4 million in 2023, then dropped by 4.17% to $3.3 million in 2024.